Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Primo N Lara

Showing results (1-10 of 274) with videos related to

Pageof 28
Sort By:
Clinical Lung Cancer|March 4, 2006
Molecular selection for therapy of patients with non-small-cell lung cancer and impaired performance status: has the time come?Primo N Lara
Cancer Investigation|November 25, 2003
Adjuvant therapy in completely resected malignant thymomaPrimo N Lara
Annual Review of Medicine|November 18, 2017
Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell TypeMamta Parikh, Primo N Lara
Kidney Cancer (Clifton, Va.)|October 10, 2022
Evaluating the Optimal Duration of Immunotherapy in Kidney CancerMamta Parikh, Primo N Lara
The Journal of Urology|July 22, 2018
Editorial CommentMarc Dall'Era, Primo N Lara
Kidney Cancer (Clifton, Va.)|October 11, 2021
Defining the Optimal Management Strategy for Small Renal MassesMarc Dall'Era, Primo N Lara
Current Problems in Cancer|June 17, 2023
PrefaceLorenzo Nardo, Primo N Lara
Clinical Lung Cancer|August 8, 2007
Optimizing targeted therapy in patients with lung cancer with a performance status of 2Primo N Lara, Angela M Davies
The New England Journal of Medicine|September 26, 2015
Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple KinasesDavid I Quinn, Primo N Lara
Critical Reviews in Oncology/Hematology|February 27, 2003
Renal cell carcinoma: current status and future directionsCynthia L Martel, Primo N Lara
Pageof 28

Showing results (1-10 of 274) with videos related to

Sort By:
Pageof 28
Clinical Lung Cancer|March 4, 2006
Molecular selection for therapy of patients with non-small-cell lung cancer and impaired performance status: has the time come?Primo N Lara
Cancer Investigation|November 25, 2003
Adjuvant therapy in completely resected malignant thymomaPrimo N Lara
Annual Review of Medicine|November 18, 2017
Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell TypeMamta Parikh, Primo N Lara
Kidney Cancer (Clifton, Va.)|October 10, 2022
Evaluating the Optimal Duration of Immunotherapy in Kidney CancerMamta Parikh, Primo N Lara
The Journal of Urology|July 22, 2018
Editorial CommentMarc Dall'Era, Primo N Lara
Kidney Cancer (Clifton, Va.)|October 11, 2021
Defining the Optimal Management Strategy for Small Renal MassesMarc Dall'Era, Primo N Lara
Current Problems in Cancer|June 17, 2023
PrefaceLorenzo Nardo, Primo N Lara
Clinical Lung Cancer|August 8, 2007
Optimizing targeted therapy in patients with lung cancer with a performance status of 2Primo N Lara, Angela M Davies
The New England Journal of Medicine|September 26, 2015
Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple KinasesDavid I Quinn, Primo N Lara
Critical Reviews in Oncology/Hematology|February 27, 2003
Renal cell carcinoma: current status and future directionsCynthia L Martel, Primo N Lara
Pageof 28